Article Versions Notes

Qureshi S, Boily G, Boulanger J, Golo KT, Guédon A-C, Lehuédé C, Roussafi F, Truchon C, Strumpf E. Advanced Lung Cancer Patients’ Use of EGFR Tyrosine Kinase Inhibitors and Overall Survival: Real-World Evidence from Quebec, Canada. Current Oncology. 2022; 29(11):8043-8073. https://doi.org/10.3390/curroncol29110636

Qureshi, Samia, Gino Boily, Jim Boulanger, Kossi Thomas Golo, Aude-Christine Guédon, Camille Lehuédé, Ferdaous Roussafi, Catherine Truchon, and Erin Strumpf. 2022. "Advanced Lung Cancer Patients’ Use of EGFR Tyrosine Kinase Inhibitors and Overall Survival: Real-World Evidence from Quebec, Canada" Current Oncology 29, no. 11: 8043-8073. https://doi.org/10.3390/curroncol29110636

Qureshi, S., Boily, G., Boulanger, J., Golo, K. T., Guédon, A.-C., Lehuédé, C., Roussafi, F., Truchon, C., & Strumpf, E. (2022). Advanced Lung Cancer Patients’ Use of EGFR Tyrosine Kinase Inhibitors and Overall Survival: Real-World Evidence from Quebec, Canada. Current Oncology, 29(11), 8043-8073. https://doi.org/10.3390/curroncol29110636